LeMaitre Vascular Q2 sales slightly miss estimates

LeMaitre Vascular

04/08/2026 21:40

Overview
US vascular device maker's Q2 sales rose 10% yr/yr, slightly missing analyst expectations
EPS for Q2 rose 23% yr/yr
Company attributes growth to Artegraft sales and international expansion

Outlook
LeMaitre sees Q3 sales of $66.3 mln-$68.3 mln and EPS of $0.66-$0.71
Company expects Q4 sales of $71.1 mln-$73.1 mln and EPS of $0.75-$0.81
LeMaitre forecasts full-year sales of $274.3 mln-$278.3 mln and EPS of $2.84-$2.94

Result Drivers
ARTEGRAFT SALES - Co said Artegraft sales increased 34% in Q2, with international launch driving growth, per CEO George LeMaitre
PRODUCT LINE RECORDS - Grafts, carotid shunts, and patches each posted record sales, with grafts up 23%, shunts up 18%, and patches up 4%
GROSS MARGIN GAINS - Co attributed 210 bps gross margin increase to higher prices, mix shift, and operational efficiencies

Company press release: ID:nGNX5VM0S1

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Slight Miss*
$70.38 mln
$70.97 mln (9 Analysts)
Q2 Net Income
 
$17.05 mln
 
Q2 Gross Profit
 
$50.76 mln
 
Q2 Income From Operations
 
$20.40 mln
 
Q2 Pretax Profit
 
$22.19 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for LeMaitre Vascular Inc is $120.00, about 15.8% above its August 3 closing price of $103.61
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 37 three months ago

Reuters Recommended Reads
Aug 3 - Inspire Medical Q2 revenue falls less than expected
Aug 4 - UK's Smith+Nephew cuts 2026 revenue view on weak US knee implant demand
Aug 3 - UFP Technologies Q2 revenue beats estimates on the back of medtech segment

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)